Ascend Laboratories, LLC recalls
12 recall notices naming Ascend Laboratories, LLC since January 2025, in United States. The most recent was published 28 Oct 2026.
12recalls on record
Latest recalls (12)
- FDAAscend Laboratories, LLC recalls Amlodipine and Olmesartan Medoxomil TabletsFDAOut of specification due to dissolution.
- FDAAscend Laboratories, LLC recalls Dabigatran Etexilate CapsulesFDAFailed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total…
- FDAAscend Laboratories, LLC recalls Dabigatran etexilate CapsulesFDAFailed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II,…
- FDAAscend Laboratories, LLC recalls Amlodipine and Olmesartan Medoxomil TabletsFDAFailed Dissolution Specifications; Olmesartan Medoxomil content below specifications
- FDAAscend Laboratories, LLC recalls Minocycline Hydrochloride Extended-Release TabletsFDAFailed Dissolution Specifications: An out-of-specification (OOS) result was observed during the 9th month of dissolution test analysis
- FDAAscend Laboratories, LLC recalls Amlodipine and Olmesartan Medoxomil TabletsFDAFailed Dissolution Specifications: Olmesartan Medoxomil content below specifications
- FDAAscend Laboratories, LLC recalls Ascend LaboratoriesFDAFailed Dissolution Specifications
- FDAAscend Laboratories, LLC recalls Atorvastatin Calcium Tablets USPFDAFailed Dissolution Specifications
- FDAAscend Laboratories, LLC recalls Aripiprazole TabletsFDASuperpotent drug
- FDAAscend Laboratories, LLC recalls Amlodipine and Olmesartan Medoxomil TabletsFDAFailed Dissolution Specifications: low dissolution results
- FDAAscend Laboratories, LLC recalls Rizatriptan Benzoate TabletsFDACGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
- FDAAscend Laboratories, LLC recalls Cephalexin for Oral SuspensionFDAFailed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of…